NCT00502086View on ClinicalTrials.gov

Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
CirrhosisChronic Hepatitis C
Interventions
DIETARY_SUPPLEMENT

Viusid (nutritional supplement)

Viusid three sachets daily during 96 weeks

OTHER

Placebo

Placebo three sachets daily during 96 weeks

Trial Locations (1)

10400

National Institute of Gastroenterology, Plaza de la Revolución

All Listed Sponsors
lead

Catalysis SL

INDUSTRY

NCT00502086 - Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. | Biotech Hunter | Biotech Hunter